Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Journal Scan / Research · May 09, 2023

Response to Checkpoint Inhibition and Targeted Therapy in Patients With Melanoma With Concurrent Haematological Malignancies

European Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies
Eur. J. Cancer 2023 Jun 01;186(xx)27-37, OJ Van Not, AJM van den Eertwegh, JB Haanen, RS van Rijn, MJB Aarts, FWPJ van den Berkmortel, CU Blank, MJ Boers-Sonderen, MJM van Eijs, JB de Groot, GAP Hospers, E Kapiteijn, M de Meza, D Piersma, M Stevense-den Boer, AAM van der Veldt, G Vreugdenhil, MWJM Wouters, KPM Suijkerbuijk, WAM Blokx

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading